News Shortcuts from other journals

Drug safety is too important to leave to industry

BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.334.7587.230 (Published 01 February 2007) Cite this as: BMJ 2007;334:230

There's a fundamental tension in many drug trials between the sponsors, who want the trial to be a useful marketing tool, and the guardians of public health, who want it to answer key questions about whether a drug works and is safe. Ideally, a trial should do both, but when …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe